Study Shows Roche's Perjeta Extended Lives of Breast Cancer Patients by 15.7 Months
Adding Perjeta to Herceptin and docetaxel chemotherapy extended the lives of people with previously untreated HER2-positive metastatic breast cancer
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | HER2 | Herceptin | Pharmaceuticals | Study | Taxotere